Allergic Rhinitis Market Size

Allergic Rhinitis Market size was estimated at USD 15.4 billion in 2024 and is projected to attain USD 23.5 billion in 2037,  surging at a CAGR of 3.6% during the forecast period i.e. 2025 to 2037. In 2025, the industry size of allergic rhinitis is assessed at USD 15.9 billion.

The allergic rhinitis industry is fostering significantly owing to the rising global incidences of allergic conditions. For instance, in April 2020, it was published in The LANCET Global Health that the cases of allergic rhinitis among children aged between 6-7 years were 11.3% and 24.4% in children aged between 13-14 years. In addition, there are rising environmental pollution, climate change, and increasing incidences of urbanization factors that raise the exposure levels to allergen agents and, therefore, to allergic rhinitis cases.

Increasing awareness of symptoms and treatment options has led to more individuals seeking to be diagnosed and treated. New pharmaceutical formulations such as novel antihistamines, intranasal corticosteroids, and biologic therapies that provide potentially better and safer profiles are responsible for fueling the market. For instance, in October 2024, GSK plc reported positive results from the phase III clinical trials ANCHOR-1 and ANCHOR-2. In this trial, depemokimab showed efficacy as well as safety in comparison to placebo in adults with CRSwNP. Furthermore, improved medical care accessibility in developing economies is also contributing to further expansion in the market.